Korea Institute of Science and Technology has described diosgenin derivatives reported to be useful for the treatment of depression, multiple sclerosis, ischemic stroke, schizophrenia, amyotrophic lateral sclerosis, neuroblastoma, Alzheimer’s disease and post-traumatic stress disorders.
Shanghai Yi Zhong Xing Biotechnology Co. Ltd. has divulged serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1) inhibitors reported to be useful for the treatment of cancer.
University of Florida has identified σ receptor ligands reported to be useful for the treatment of cancer, depression, neurodegeneration, stroke, pain, multiple sclerosis, schizophrenia and anxiety.
Hua Medicine (Shanghai) Co. Ltd. has synthesized ketohexokinase (KHK) inhibitors reported to be useful for the treatment of gout, stroke, coronary artery disease, irritable bowel syndrome, diabetes, cataracts, fibrosis and obesity.
Cytokinetics Inc. has disclosed nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) activators reported to be useful for the treatment of cancer, neurodegeneration, mitochondrial and metabolic diseases, cardiovascular, muscle, renal and inflammatory disorders, among others.
The first patenting from South Korea’s Neudive Inc. sees its CEO, SungJa Cho, applying for protection of the company’s mobile digital social therapy device, NDTx-01, which helps build the social skills of neurodiverse individuals, and in particular children and adolescents with autism spectrum disorder and social communication disorder.
Shenzhen Yangli Pharmaceutical Technology Co. Ltd. has patented poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer, ischemia and neurodegeneration.
Adlai Nortye Biopharma Co. Ltd. has divulged molecular glue degraders acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers reported to be useful for the treatment of cancer, viral infections, autoimmune disease and inflammatory disorders.
Onquality Pharmaceuticals China Ltd. has described cyclin-dependent kinase 4 (CDK4) and/or cyclin-dependent kinase 6 (CDK6) inhibitors reported to be useful for the treatment of cancer therapy-associated disorders.
RSS
